MEM-288 is under clinical development by Memgen and currently in Phase I for Triple-Negative Breast Cancer (TNBC). According to GlobalData, Phase I drugs for Triple-Negative Breast Cancer (TNBC) have an 83% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how MEM-288’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
MEM-288 is under development for the treatment of solid tumors including non-small cell lung cancer, cutaneous squamous cell carcinoma, Merkel cell carcinoma, melanoma pancreatic cancer, triple negative breast cancer and head and neck cancer. It is administered through intratumor route. The drug candidate is an oncolytic virus expressing CD40 ligand (CD40L) and interferon-beta (IFN-beta). It acts by targeting cells expressing CD40.
Memgen LLC (Memgen) is a biotechnology company that discovers, designs and develops viral immunotherapies for the treatment of lung, breast, pancreatic, and prostate cancers. Memgen is headquartered in Houston, Texas, the US.
For a complete picture of MEM-288’s drug-specific PTSR and LoA scores, buy the report here.